Opinion statement
Patients with acute ischemic stroke should be immediately transported to the nearest hospital for rapid evaluation and treatment. Intravenous t-PA within 3 hours of symptom onset is the recommended treatment for patients who meet the National Institute of Neurological Disorders and Stroke (NINDS) study eligibility criteria. Patients should be informed of the risk of symptomatic cerebral hemorrhage, and strict adherence to the NINDS study protocol is strongly recommended to optimize the risk-benefit ratio. Ischemic stroke patients who are not eligible for t-PA therapy should usually be started on aspirin. Intravenous heparin is not recommended as a standard treatment but may be considered for specific patient subgroups. Low-dose subcutaneous heparin is recommended for prophylaxis of deep vein thrombosis in immobilized patients. Management of stroke patients by a designated stroke team is recommended to facilitate prompt diagnosis and treatment and early initiation of rehabilitation therapy. We also recommend that physicians who manage patients with acute stroke maintain contact with local or regional stroke centers to facilitate referral of appropriate patients for intensive care or specialized diagnostic tests or therapies.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Adams HP, Brott TG, Crowell RM, et al.: Guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994, 25:1901–1914.
Adams HP, Brott TG, Furlan AJ, et al.: Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1996, 27:1711–1718.
Albers GW, Easton JD, Sacco RL, Teal P: Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 1998, 114:683S-698S.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333:1581–1587. In this trial, patients treated with intravenous t-PA at a dose of 0.9 mg/kg begun within 3 hours of symptom onset were at least 30% more likely to have a favorable outcome (absolute benefit 11% to 13%) after 3 months when compared with patients given placebo. In addition, there was no increase in the number of early or late deaths or in late disability attributable to t-PA. Since these favorable results were not replicated by the ECASS trials and the streptokinase trials, the protocol and the inclusion and exclusion criteria of this study should be followed closely when intravenous t-PA is administered to patients with stroke.
The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group: A systems approach to immediate evaluation and management of hyperacute stroke: experience at eight centers and implications for community practice and patient care. Stroke 1997, 28:1530–1540. This paper describes specific measures to minimize the amount of time between stroke onset and treatment. These measures include community education and coordination among emergency medical services and stroke teams. Standard orders, patient selection criteria for intravenous t-PA therapy, and algorithms for management of elevated blood pressure and suspected intracranial hemorrhage are provided.
Hacke W, Kaste M, Fieschi C, et al.: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995, 274:1017–1025. This trial demonstrated that intravenous t-PA in a dose of 1.1 mg/kg given to patients with hemispheric stroke within 6 hours of symptom onset was associated with increased cerebral hemorrhage and early death, especially in patients with CT signs of early infarction involving more than 33% of the MCA territory.
Hacke W, Kaste M, Fieschi C, et al.: Randomised doubleblind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998, 352:1245–1251. In this recently published study, intravenous t-PA in a dose of 0.9 mg/kg was given within 6 hours of stroke onset using a protocol similar to that of the NINDS study. No significant benefits or risks were detected in this trial. In addition, preliminary reports suggest that CT signs of early infarction did not seem to predict the clinical response to intravenous t-PA in this study.
Clark WM, Albers GW, for the ATLANTIS Stroke Study Investigators: The ATLANTIS rt-PA (alteplase) acute stroke trial: final results. Stroke 1999, 30:234.
von Kummer R, Allen KL, Holle R, et al.: Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology 1997, 205:327–333.
International Stroke Trial Collaborative Group: The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997, 349:1569–1581. In this study, the use of subcutaneous heparin was not found to reduce significantly the risk of early stroke recurrence. Even in the subgroup with atrial fibrillation, the reduction in recurrence of ischemic stroke with subcutaneous heparin (2.8% versus 4.9%) was largely counterbalanced by an increase in hemorrhagic stroke (2.1% versus 0.4%), rendering the net benefit not significant.
CAST (Chinese Acute Stroke Trial) Collaborative Group: CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997, 349:1641–1649. Aspirin started within 48 hours of ischemic stroke onset at a dose of 160 to 300 mg daily resulted in nine fewer deaths or nonfatal strokes during the first 2 to 4 weeks and 13 fewer deaths or cases of dependency in 4 weeks to 6 months after stroke onset per 1000 patients treated.
The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators: Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998, 279:1265–1272. This study classified the causes of stroke into the subgroups of large artery atherosclerosis, cardioembolism, small vessel disease, and uncertain cause. Although no overall benefit at 3 months was demonstrated with the use of intravenous danaparoid, on subgroup analysis there were significantly more patients with large artery atherosclerosis who had a favorable outcome at 3 months in the group treated with danaparoid.
Caplan LR, Mohr JP, Kistler JP: Thrombolysis—not a panacea for ischemic stroke. N Engl J Med 1997, 337:1309–1310.
Wardlaw JM, Warlow CP, Counsell C: Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet 1997, 350:607–614.
Lutsep HL, Albers GW, DeCrespigny A, et al.: Clinical utility of diffusion-weighted magnetic resonance imaging in the assessment of ischemic stroke. Ann Neurol 1997, 41:574–580. Diffusion-weighted imaging is especially useful in early detection and localization of brain infarction within 48 hours of stroke onset, particularly for small subcortical and brain stem infarcts. It also allows one to distinguish between acute and chronic infarcts.
Patel MR, Edelman RR, Warach S: Detection of hyperacute primary intraparenchymal hemorrhage by magnetic resonance imaging. Stroke 1996, 27:2321–2324. In this study, magnetic resonance susceptibility-weighted gradientecho images and echo-planar imaging T2-weighted images were able to demonstrate acute cerebral hemorrhage with a core of signal loss and a rim of surrounding hyperintensity. Other magnetic resonance techniques are also being evaluated to detect subarachnoid or intraventricular hemorrhages. These techniques may render the CT scan unnecessary for the exclusion of intracranial bleeding in the evaluation of acute stroke.
Alexandrov AV, Bladin CF, Norris JW: Intracranial blood flow velocities in acute ischemic stroke. Stroke 1994, 25:1378–1383.
Wildermuth S, Knauth M, Brandt T, et al.: Role of CT angiography in patient selection for thrombolytic therapy in acute hemispheric stroke. Stroke 1998, 29:935–938.
Firlik AD, Rubin G, Yonas H, Wechsler LR: Relation between cerebral blood flow and neurologic deficit resolution in acute ischemic stroke. Neurology 1998, 51:177–182.
Ueda T, Hatakeyama T, Kumon Y, et al.: Evaluation of risk of hemorrhagic transformation in local intra-arterial thrombolysis in acute ischemic stroke by initial SPECT. Stroke 1994, 25:298–303.
Firlik AD, Yonas H, Kaufmann A, et al.: Relationship between cerebral blood flow and the development of swelling and life-threatening herniation in acute ischemic stroke. J Neurosurg 1998, 89:243–249.
Hunter GJ, Hamberg LM, Ponzo JA, et al.: Assessment of cerebral perfusion and arterial anatomy in hyperacute stroke with three-dimensional functional CT: early clinical results. Am J Neuroradiol 1998, 19:29–37.
Baird AE, Benfield A, Schlaug G, et al.: Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol 1997, 41:581–589.
Rordorf G, Koroshetz WJ, Copen WA, et al.: Regional ischemia and ischemic injury in patients with acute middle cerebral artery stroke as defined by early diffusion-weighted and perfusion-weighted MRI. Stroke 1998, 29:939–943.
Stroke Unit Trialists’ Collaboration: Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke. BMJ 1997, 314:1151–1159. Compared with management of patients with stroke in a general medical ward, the care of patients with stroke by an organized in-patient stroke service resulted in reductions in mortality, dependency, and long-term institutionalization. Length of stay in a hospital or institution was also reduced.
Reith J, Jørgensen HS, Pedersen PB, et al.: Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet 1996, 347:422–425.
Weir CJ, Murray GD, Dyker AG, Lees KR: Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study. BMJ 1997, 314:1303–1306.
Norris JW, Hachinski VC: High dose steroid treatment in cerebral infarction. BMJ 1986, 292:21–23.
Norton B, Homer-Ward M, Donnelly MT, et al.: A randomised prospective comparison of percutaneous endoscopic gastrostomy and nasogastric tube feeding after acute dysphagic stroke. BMJ 1996, 312:13–16.
Chen HJ, Lee TC, Wei CP: Treatment of cerebellar infarction by decompressive suboccipital craniectomy. Stroke 1992, 23:957–961.
Schwab S, Steiner T, Aschoff A, et al.: Early hemicraniectomy in patients with complete middle cerebral artery infarction. Stroke 1998, 29:1888–1893. In this series, hemicraniectomy was performed on 63 patients with complete middle cerebral artery (MCA) territory infarction and was associated with a surprisingly high survival rate of 73%. None of the survivors was wheelchair bound. Suitable patients who may be considered for hemicraniectomy may include patients younger than 70 years of age with massive MCA stroke in the nondominant hemisphere or with only incomplete aphasia before deterioration.
Rordorf G, Cramer SC, Efird JT, et al.: Pharmacological elevation of blood pressure in acute stroke: clinical effects and safety. Stroke 1997, 28:2133–2138.
Hacke W, Schwab S, Horn M, et al.: “Malignant” middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol 1996, 53:309–315. In a series of 55 patients with complete middle cerebral artery territory infarction who received intensive care unit treatment, only 12 survived. All deaths were due to transtentorial herniation.
Alexandrov AV, Pullicino PM, Meslin EM, Norris JW, for the members of the Canadian and Western New York Stroke Consortiums: Agreement on disease-specific criteria for do-not-resuscitate orders in acute stroke. Stroke 1996, 27:232–237.
Chiu D, Krieger D, Villar-Cordova C, et al.: Intravenous tissue plasminogen activator for acute ischemic stroke. Feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998, 29:18–22.
Grond M, Stenzel C, Schmülling S, et al.: Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998, 29:1544–1549.
The Multicenter Acute Stroke Trial-Europe Study Group: Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996, 335:145–150.
Multicentre Acute Stroke Trial-Italy (MAST-I) Group: Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995, 345:1509–1514.
Donnan GA, Davis SM, Chambers BR, et al.: Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996, 276:961–966.
The NINDS t-PA Stroke Study Group: Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997, 28:2109–2118.
Fagan SC, Morgenstern LB, Petitta A, et al.: Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998, 50:883–890.
Einhäupl KM, Villringer A, Meister W, et al.: Heparin treatment in sinus venous thrombosis. Lancet 1991, 338:597–600.
Gönner F, Remonda L, Mattle H, et al.: Local intra-arterial thrombolysis in acute ischemic stroke. Stroke 1998, 29:1894–1900.
Brandt T, von Kummer R, Müller-Küppers M, Hacke W: Thrombolytic therapy of acute basilar artery occlusion, variables affecting recanalization and outcome. Stroke 1996, 27:875–881.
Furlan AJ, Higashida R, Wechsler L, Schulz G: PROACT II: recombinant prourokinase (r-ProUK) in acute cerebral thromboembolism. Initial trial results [abstract]. Stroke 1999, 30:234.
Ueda T, Sakaki S, Nochide I, et al.: Angiography after intra-arterial thrombolysis for acute occlusion of intracranial arteries. Stroke 1998, 29:2568–2574.
Nakano S, Yokogami K, Ohta H, et al.: Direct percutaneous transluminal angioplasty for acute middle cerebral artery occlusion. Am J Neuroradiol 1998, 19:767–772.
Gasecki AP, Ferguson GG, Eliasziw M, et al.: Early endarterectomy for severe carotid artery stenosis after a nondisabling stroke: results from the North American Symptomatic Carotid Endarterectomy Trial. J Vasc Surg 1994, 20:288–295.
Sherman DG, for the STAT Writers Group: Defibrinogenation with Viprinex (Ancrod) for the treatment of acute, ischemic stroke [abstract]. Stroke 1999, 30:234.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chan, B.P., Albers, G.W. Acute ischemic stroke. Curr Treat Options Neurol 1, 83–95 (1999). https://doi.org/10.1007/s11940-999-0009-5
Issue Date:
DOI: https://doi.org/10.1007/s11940-999-0009-5